Clínic Barcelona

Biomarkers of response to CAR T-cell therapy with ARI-0002h in refractory multiple myeloma are described

A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targeting the B-cell maturation antigen (BCMA) in people with refractory multiple myeloma.

Related contents
Keep reading about:

Related news